C4 Therapeutics (CCCC) Competitors $2.41 +0.18 (+8.07%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$2.42 +0.01 (+0.58%) As of 10/9/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CCCC vs. SIGA, IVA, CMPS, MNPR, ARCT, SVRA, KALV, GOSS, OPT, and BCYCShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Siga Technologies (SIGA), Inventiva (IVA), COMPASS Pathways (CMPS), Monopar Therapeutics (MNPR), Arcturus Therapeutics (ARCT), Savara (SVRA), KalVista Pharmaceuticals (KALV), Gossamer Bio (GOSS), Opthea (OPT), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Its Competitors Siga Technologies Inventiva COMPASS Pathways Monopar Therapeutics Arcturus Therapeutics Savara KalVista Pharmaceuticals Gossamer Bio Opthea Bicycle Therapeutics Siga Technologies (NASDAQ:SIGA) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation. Is SIGA or CCCC more profitable? Siga Technologies has a net margin of 45.73% compared to C4 Therapeutics' net margin of -325.88%. Siga Technologies' return on equity of 40.52% beat C4 Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Siga Technologies45.73% 40.52% 35.62% C4 Therapeutics -325.88%-53.91%-33.26% Which has more risk and volatility, SIGA or CCCC? Siga Technologies has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.94, suggesting that its stock price is 194% more volatile than the S&P 500. Do insiders and institutionals hold more shares of SIGA or CCCC? 55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 2.0% of Siga Technologies shares are held by company insiders. Comparatively, 8.7% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer SIGA or CCCC? In the previous week, Siga Technologies had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Siga Technologies and 3 mentions for C4 Therapeutics. Siga Technologies' average media sentiment score of 0.99 beat C4 Therapeutics' score of 0.62 indicating that Siga Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, SIGA or CCCC? Siga Technologies has higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSiga Technologies$138.72M4.36$59.21M$1.137.47C4 Therapeutics$35.58M4.82-$105.32M-$1.58-1.53 Do analysts recommend SIGA or CCCC? C4 Therapeutics has a consensus price target of $8.50, indicating a potential upside of 252.70%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than Siga Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00C4 Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 SummarySiga Technologies beats C4 Therapeutics on 9 of the 16 factors compared between the two stocks. Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$158.71M$3.37B$6.14B$10.65BDividend YieldN/A2.29%5.66%4.70%P/E Ratio-1.5321.3485.8427.65Price / Sales4.82472.60621.93138.22Price / CashN/A47.1938.3262.20Price / Book0.7910.4313.066.79Net Income-$105.32M-$52.40M$3.30B$275.88M7 Day Performance6.17%4.97%3.72%1.90%1 Month Performance-8.71%17.02%10.70%8.90%1 Year Performance-54.53%34.38%84.94%36.28% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics3.6437 of 5 stars$2.41+8.1%$8.50+252.7%-52.4%$158.71M$35.58M-1.53150Analyst ForecastSIGASiga Technologies1.9823 of 5 stars$8.23-8.0%N/A+29.1%$640.87M$138.72M7.2840Positive NewsAnalyst ForecastIVAInventiva3.2835 of 5 stars$6.24-4.4%$15.57+149.5%+227.2%$624.67M$9.95M0.00100News CoverageAnalyst ForecastGap DownHigh Trading VolumeCMPSCOMPASS Pathways3.0537 of 5 stars$6.29-2.2%$16.29+158.9%+6.8%$616.90MN/A-3.42120Analyst ForecastMNPRMonopar Therapeutics1.4982 of 5 stars$99.50+0.1%$97.33-2.2%+1,887.4%$613.23MN/A-29.8810Analyst ForecastARCTArcturus Therapeutics2.8608 of 5 stars$21.01-6.9%$50.57+140.7%-10.1%$612.61M$152.31M-9.42180Analyst ForecastSVRASavara2.8028 of 5 stars$3.46-0.9%$7.50+116.8%-6.3%$603.20MN/A-6.9220Trending NewsAnalyst ForecastKALVKalVista Pharmaceuticals3.794 of 5 stars$10.96-7.5%$26.43+141.1%+5.1%$598.70M$1.43M-2.78100Analyst ForecastGOSSGossamer Bio3.9514 of 5 stars$2.41-6.2%$8.50+252.7%+153.5%$584.37M$114.70M-3.89180Analyst ForecastOPTOpthea0.3453 of 5 stars$3.41+7.2%$1.33-60.9%-27.6%$583.10M$30K0.008Gap UpHigh Trading VolumeBCYCBicycle Therapeutics3.7819 of 5 stars$8.23-1.7%$22.22+170.0%-63.9%$580.09M$35.28M-2.34240 Related Companies and Tools Related Companies Siga Technologies Competitors Inventiva Competitors COMPASS Pathways Competitors Monopar Therapeutics Competitors Arcturus Therapeutics Competitors Savara Competitors KalVista Pharmaceuticals Competitors Gossamer Bio Competitors Opthea Competitors Bicycle Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CCCC) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredElon callingElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | SponsoredNvidia and AMD just surged. But this setup was already winning.Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
